Cardiac sympathetic activity in chronic heart failure: Cardiac123i-mIBG scintigraphy to improve patient selection for ICD implantation

Netherlands Heart Journal

Volumn 24, Issue 12, 2016, Pages 701-708

  Verschure, D O ^a,b   van Eck Smit, B L F ^a   Somsen, G A ^c   Knol, R J J ^d   Verberne, H J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ZAANS MEDICAL CENTER   (Netherlands)

^c Cardiology Centers of the Netherlands   (Netherlands)

^d Location Alkmaar   (Netherlands)

Author keywords

123I mIBG scintigraphy; Cardiac resynchronisation therapy; Cardiac sympathetic activity; Heart failure; Implantable cardioverter defibrillator; Prognosis

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; NORADRENALIN; POTASSIUM IODIDE; TETROFOSMIN;

CARDIAC RESYNCHRONIZATION THERAPY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART SCINTISCANNING; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERACTIVITY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT SELECTION; PHOTON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; REVIEW; SYMPATHETIC TONE;

EID: 85002808139     PISSN: 15685888     EISSN: 18766250     Source Type: Journal    
DOI: 10.1007/s12471-016-0902-y     Document Type: Review

References (50)

1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8:30–41.
2. Engelfriet P, Hoogenveen R, Poos MJJC, Blokstra A, van Baal P, Verschuren W. Hartfalen: epidemiologie, risicofactoren en de toekomst. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu (RIVM); 2012.
3. Koopman C, van Dis I, Bots M, Vaartjes I. Hartfalen. 2012.
4. Bots ML, Buddeke J, van Dis I, Vaartjes I, Visseren FLJ. Hart- en vaatziekten in Nederland 2015. Zoetermeer: Hartstichting; 2015. ISBN 9789075131789.
5. RIVM. Kosten van Ziekten database 2013. www.volksgezondheidenzorg.info. Accessed 15 May 2016
6. Maggioni AP, Dahlstrom U, Filippatos G, et al. EUR Observational research programme: regional differences and 1-year follow-up results of the heart failure pilot survey (ESC-HF pilot). Eur J Heart Fail. 2013;15:808–17.
7. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an Implantable Defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.
8. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.
9. Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the cardiac resynchronization-heart failure (CARE-HF) trial. Eur J Heart Fail. 2012;14:628–34.
10. Cleland JGF, Daubert J-C, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
11. Ponikowski PVA, Anker SD, Bueno H, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;2016(37):2129–200.
12. Moss AJ, Greenberg H, Case RB, et al. Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation. 2004;110:3760–5.
13. Pires LA, Abraham WT, Young JB, Johnson KM. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials. Am Heart J. 2006;151:837–43.
14. de Haan S, de Boer K, Commandeur J, Beek AM, van Rossum AC, Allaart CP. Assessment of left ventricular ejection fraction in patients eligible for ICD therapy: discrepancy between cardiac magnetic resonance imaging and 2D echocardiography. Neth Heart J. 2014;22:449–55.
15. Scholtens AM, Braat AJ, Tuinenburg A, Meine M, Verberne HJ. Cardiac sympathetic innervation and cardiac resynchronization therapy. Heart Fail Rev. 2014;19:567–73.
16. Pierpont GL, DeMaster EG, Reynolds S, Pederson J, Cohn JN. Ventricular myocardial catecholamines in primates. J Lab Clin Med. 1985;106:205–10.
17. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73:615–21.
18. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–23.
19. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169–75.
20. Merlet P, Delforge J, Syrota A, et al. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation. 1993;87:1169–78.
21. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205–11.
22. Werner RA, Rischpler C, Onthank D, et al. Retention kinetics of the 18F-labeled sympathetic nerve PET tracer LMI1195: comparison with 11C-hydroxyephedrine and 123I-MIBG. J Nucl Med. 2015;56:1429–33.
23. Thackeray JT, Bengel FM. Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol. 2013;20:150–65.
24. Travin MI. Cardiac autonomic imaging with SPECT tracers. J Nucl Cardiol. 2013;20:128–43, quiz 46.
25. Sinusas AJ, Lazewatsky J, Brunetti J, et al. Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18Flabeled tracer for imaging myocardial innervation. J Nucl Med. 2014;55:1445–51.
26. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252–8.
27. Wichter T, Hindricks G, Lerch H, et al. Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy. An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation. 1994;89:667–83.
28. Shimizu M, Ino H, Yamaguchi M, et al. Heterogeneity of cardiac sympathetic nerve activity and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Nucl Med. 2002;43:15–20.
29. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.
30. Verschure DO, Bongers V, Hagen P, Somsen GA, van Eck-Smit BF, Verberne H. Impact of a predefined mediastinal ROI on inter-observer variability of planar 123I-MIBG heart-to-mediastinum ratio. J Nucl Cardiol. 2014;21:605–13.
31. Pellegrino T, Petretta M, de Luca S, et al. Observer reproducibility of results from a low-dose 123I-metaiodobenzylguanidine cardiac imaging protocol in patients with heart failure. Eur J Nucl Med Mol Imaging. 2013;40:1549–57.
32. Flotats A, Carrió I, Agostini D, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.
33. Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535–46.
34. Chen J, Garcia EV, Galt JR, Folks RD, Carrio I. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol. 2006;13:251–60.
35. Garcia EV, Faber TL, Cooke CD, Folks RD, Chen J, Santana C. The increasing role of quantification in clinical nuclear cardiology: the Emory approach. J Nucl Cardiol. 2007;14:420–32.
36. Holly TA, Abbott BG, Al-Mallah M, et al. Single photon-emission computed tomography. J Nucl Cardiol. 2010;17:941–73.
37. Bax JJ, Kraft O, Buxton AE, et al. 123 I-mIBG scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131–40.
38. Boogers MJ, Borleffs CJW, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769–77.
39. Verschure DO, Veltman CE, Manrique A, et al. For what endpoint does myocardial 123I-MIBG scintigraphy have the greatest prognostic value in patients with chronic heart failure? Results of a pooled individual patient data meta-analysis. Eur Heart J Cardiovasc Imaging. 2014;15:996–1003.
40. Kioka H, Yamada T, Mine T, et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93:1213–8.
41. Al Badarin FJ, Wimmer AP, Kennedy KF, Jacobson AF, Bateman TM. The utility of ADMIRE-HF risk score in predicting serious arrhythmic events in heart failure patients: incremental prognostic benefit of cardiac 123I-mIBG scintigraphy. J Nucl Cardiol. 2014;21:756–62, quiz 3–55, 63–5.
42. Nakajima K, Nakata T, Yamada T, et al. A prediction model for 5-year cardiac mortality in patients with chronic heart failure using (1)(2)(3)I-metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging. 2014;41:1673–82.
43. Simoes MV, Barthel P, Matsunari I, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004;25:551–7.
44. Sasano T, Abraham MR, Chang KC, et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008;51:2266–75.
45. Marshall A, Cheetham A, George RS, Mason M, Kelion AD. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention. Heart. 2012;98:1359–65.
46. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121–31.
47. Travin MI, Henzlova MJ, van Eck-Smit BL, et al. Assessment of I-mIBG and Tc-tetrofosmin single-photon emission computed tomographic images for the prediction of arrhythmic events in patients with ischemic heart failure: Intermediate severity innervation defects are associated with higher arrhythmic risk. J Nucl Cardiol. 2016; doi:10.1007/s12350-015-0336-8.
48. Fallavollita JA, Heavey BM, Luisi AJ Jr., et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141–9.
49. Clements IP, Kelkar AA, Garcia EV, et al. Prognostic significance of 123I-mIBG SPECT myocardial imaging in heart failure: differences between patients with ischaemic and non-ischaemic heart failure. Eur Heart J Cardiovasc Imaging. 2016;17:384–90.
50. O’Day K, Levy WC, Johnson M, Jacobson AF. Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USA. Appl Health Econ Health Policy. 2016;14:361–73.